Jorge Ratao

Brand Team Leadership • Oncology Unit P&L management • Direct report to General Manager • Launch preparation roadmap for Venetoclax (indication: CLL 3rd Line) with focus on market access and medical affairs and preparation of upcoming indications (2nd and 1st line). Venetoclax Franchise 5 years Strategic Planning • PreMarketing of Solid Tumors franchise (veliparib, Depatux-M e Rova-T) for lung cancer (SCLC and NSCLC) and Glioblastoma (GBM) – scenario and resources planning. Brand planning for 2018 onwards. • Build up the Business Unit, actually with 2 Sales Specialist, 1 Hematology Brand Manager and a BU Assistant and dotted line to medical Team (1 Medical Advisor and MSL). • Planning and implementation of new business model – Companion diagnostic model in Lung cancer market

• Direct report to General Manager • Oncology BU P&L management • Oncology Business Leadership until approval local Headcount – Oncology and Hemato-Oncology assets transition from Global to Local management. Pre Marketing plans development focused on strategic planning along 5 years and launch preparation of first asset – Venetoclax in Hemato-Oncology. Human Resources (Onco Team) planning and recruiting. • Biosimilars Value Team & Project Leadership – multi stakeholder team focused on Biosimilars development within Abbvie key markets. Strategic definition of AbbVie Value Proposition, Scenario planning and Business Optimization Plan (in market Humira biosimilar scenario).

• BU HUMIRA Rheumatology Report - 2 Brand managers and Sales Manager as direct reports, and a dedicate Sales Team of 7 Hospital Sales Rep. • Brand Team Rheumatology Leadership • Rheumatology P&L management • Direct report to Commercial Director Immunology • Team member of Biotherapeutics Task Force • Innovative Contracting (P2P, Risk sharing, ….)team member • Presidential Award 2014 due to successful CAP negotiation with INFARMED • Launch of Ultrasound School with Rheumatology Society – an innovative partnership that increased diagnosis rate and Biologics penetration.

• BU HUMIRA Rheumatology Report - 1 Brand managers and Sales Manager as direct reports, and a dedicate Sales Team of 7 Hospital Sales Rep. • Brand Team Rheumatology Leadership • Rheumatology P&L management • Direct report to Commercial Director Immunology

HUMIRA Rheumatology Leadership (represents 60% of total brand revenue). HUMIRA New Indications leadership: Gastroenterology (Crohn´s disease) and Dermatology (Psoriasis). Member of the Team “Brand Planning” - adapt and implement new strategic and operational planning guidelines. Coordination of “Brand Planning” leading the strategic planning process. Launch of Rheumatology Registry in partnership with Rheumatology Society – considered the best patient registry in Portugal and in use as RWE (real word evidence) studies support. Launch of Crohn’s Disease indication - achieved the highest growth rate in launch year in Europe (WEC region) Pre Launch activities of Psoriasis Indication Successful CAP negotiation for Humira – full market access

Strategic Planning “Brand Management”, “Sales Force Effectiveness” e “Sales Force Management” and “Organizational alignment” analytics and reports.

Marketing Department reports: 3 Brand Managers and 1 assistant Member of Astellas Management Team Areas of focus: Transplantation, Urology, Immunology, Dermatology and Oncology. Team Member of “Strategic Marketing Planning Team”of Astellas Europe - Assignment in Headquarters Team member of Marketing Intelligence Team and “European Sales Management Initiative”. Achievements: OMNIC; PROGRAF and ELIGARD market leaders

Launch OMNIC for BPH

Plasma Derivatives Therapies (Factor VIII and IgG ) Leadership